This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Arrhythmia Atrial Fibrillation Pulmonary 
Frontiers in Cardiovascular Medicine
JANUARY 21, 2025
Atrial fibrillation is the most prevalent arrhythmia with a lifetime risk of nearly 30%. Pulmonary vein isolation (PVI) is the most effective treatment for rhythm control. It can be associated with reduced quality of life and complications such as heart failure and stroke.
DAIC
APRIL 18, 2024
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. However, this reasoning disregards valuable data regarding early arrhythmia recurrences and their potential significance.
Frontiers in Cardiovascular Medicine
FEBRUARY 13, 2025
Specific cardiovascular diseases, such as acute myocardial infarction, arrhythmias, pulmonary hypertension and pericarditis, were also pointed. Elevated risk of arrhythmias, particularly atrial fibrillation, correlated with occupational silica exposure.
DAIC
DECEMBER 29, 2023
Unlike paroxysmal AF, which describes symptoms that last for seven days or fewer, persistent AF is a sustained arrhythmia that lasts for more than a week 1. Early treatment of persistent AF can reduce the risk of blood clots, stroke, and heart failure, and may prevent the disease from becoming permanent.
Dr. S. Venkatesan MD
APRIL 28, 2024
Both atria develop from a combination of the primitive atrium, sinus venous, and pulmonary veins.It When atrial fibrillation (AF) begins, it can start with a single focus, degenerating to multiple wavelets, and it spreads throughout the entire surface area of both atria. The baseline RA dimension is a few mm more than LA.
Heart BMJ
DECEMBER 23, 2024
Current guideline indications for intervention in asymptomatic patient are centred on left ventricular dimensions and ejection fraction and may include consideration in atrial fibrillation, pulmonary hypertension and those with left atrial dilatation.
HeartRhythm
MARCH 31, 2025
Whilst pulmonary vein isolation (PVI) is the key endpoint for catheter ablation therapy for atrial fibrillation (AF), it is unknown whether adjunctive carinal ablation impacts outcome beyond achieving first pass isolation.
HeartRhythm
MARCH 31, 2025
Despite advances in treatment of atrial fibrillation (AF) with pulmonary vein isolation (PVI), AF recurrence remains a challenge. High tx burden pre-PVI may lead to difficulty maintaining arrhythmia freedom post-PVI.
Frontiers in Cardiovascular Medicine
FEBRUARY 11, 2024
At present we do not have any reliable intra-procedural electrophysiologic predictors of long-term success of AF ablation other than pulmonary vein isolation. We evaluated selected intraprocedural pulmonary vein characteristics that may be helpful in future guidance of persistent AF ablation. Results PV capture was identified in 20.3%
64 
HeartRhythm
MARCH 31, 2025
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in adults, leading to significant cardiovascular complications such as ischemic stroke, heart failure, and myocardial infarction. Pulmonary vein isolation (PVI) is a well-established treatment for rhythm control in patients with AF.
Open Heart
JANUARY 18, 2024
Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy.
Frontiers in Cardiovascular Medicine
JANUARY 31, 2024
Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The rate of 12-month freedom from clinical atrial arrhythmia recurrence was 85.1%
HeartRhythm
APRIL 30, 2024
Animal studies suggest that catheter ablation-associated parasympathetic and sympathetic denervation could result in increased ventricular arrhythmias (VA). The impact of catheter ablation of atrial fibrillation on VA burden in humans has not been assessed.
HeartRhythm
MARCH 31, 2025
Catheter ablation via pulmonary vein isolation (PVI) is first-line treatment for paroxysmal atrial fibrillation (pAF). It is unclear whether additional lesions with PVI using the novel pulsed field ablation (PFA) technique affects outcomes in this population.
HeartRhythm
MARCH 31, 2025
Persistent atrial fibrillation (AF) ablation targeting extra-pulmonary vein drivers using various technologies has delivered varying results from no benefit to significant arrhythmia free survival.
HeartRhythm
MARCH 31, 2025
Pulmonary vein isolation (PVI) is an effective treatment for atrial fibrillation (AF). Baseline heart rate (HR) in normal sinus rhythm (NSR) has been observed to increase after PVI, thought to be due to modification of ganglionated plexi during PVI.
40 
European Journal of Heart Failure
FEBRUARY 25, 2025
Overview of the study population and effects observed after catheter ablation for atrial fibrillation. PVI, pulmonary vein isolation. Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF. Median AF burden reduction was 36.3
HeartRhythm
MARCH 31, 2025
Pulsed field ablation (PFA) is a promising new alternative to thermal ablation (TA) for atrial fibrillation (AF), improving safety and duration of procedure times. While pulmonary vein isolation (PVI) durability appears comparable between PFA and TA, the necessity of post-ablation remapping remains uncertain.
HeartRhythm
APRIL 30, 2024
Multiple randomized controlled trials (RCTs) have compared the efficacy of pulmonary vein isolation (PVI) adjunctive techniques with PVI alone in patients with persistent atrial fibrillation (AF).
Frontiers in Cardiovascular Medicine
JANUARY 15, 2024
Background Catheter ablation (CA) for symptomatic atrial fibrillation (AF) offers the best outcomes for patients. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation. Age >75 years ( p = 0.02, HR: 2.7,
64 
HeartRhythm
MARCH 31, 2025
Since pulmonary vein isolation (PVI)the standard treatment for atrial fibrillation (AF)is inadequate for persistent AF (PsAF), various extra-PVI strategies have been proposed.
DAIC
FEBRUARY 2, 2024
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. AFib is the most common type of cardiac arrhythmia and affects more than 6 million people in the United States and nearly 38 million people worldwide.2,3 In: AF Symposium.;
105 
Frontiers in Cardiovascular Medicine
FEBRUARY 7, 2024
Background Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with a high risk of stroke. Conclusion Our findings indicate that an enlarged left atrium and abnormal hemodynamic parameters in the left atrial and pulmonary veins are linked to a greater risk of LAT/SEC.
Frontiers in Cardiovascular Medicine
FEBRUARY 17, 2025
Backgroundwide antral pulmonary vein isolation (PVI) is effective for treating paroxysmal atrial fibrillation (PAF), although time-demanding. The primary endpoint was achieved by 9% and 12% of cases at 12 and 24 month follow up, respectively.
HeartRhythm
APRIL 30, 2024
Low voltage area (LVA) and low conduction velocity (CV) are promising risk factors to identify patients with abnormal atrial substrate at a high risk of atrial fibrillation (AF) recurrence following pulmonary vein isolation (PVI).
40 
Circulation: Arrhythmia and Electrophysiology
NOVEMBER 3, 2023
Circulation: Arrhythmia and Electrophysiology, Volume 16, Issue 11 , Page e012043, November 1, 2023. BACKGROUND:In patients with persistent atrial fibrillation (PersAF), catheter ablation aiming for pulmonary vein isolation (PVI) is associated with moderate clinical effectiveness.
Dr. Smith's ECG Blog
JANUARY 5, 2020
Here is the computer interpretation: ATRIAL FIBRILLATION WITH RAPID VENTRICULAR RESPONSE WITH ABERRANT CONDUCTION OR VENTRICULAR PREMATURE COMPLEXES LEFT AXIS DEVIATION [QRS AXIS beyone -30] NONSPECIFIC ST and T-WAVE ABNORMALITY The over-reading physician confirmed this diagnosis, which is incorrect. It is not atrial fibrillation.
Journal of Cardiovascular Electrophysiology
MARCH 27, 2025
ABSTRACT Background Ultra-low temperature cryoablation (ULTC) is a technique designed to rapidly cool cardiac tissue to extremely low temperatures, enabling the creation of ablation lesions for the treatment of atrial fibrillation (AF). Arrhythmia outcomes after repeat ablation were evaluated.
HeartRhythm
MARCH 31, 2025
Radiofrequency catheter ablation (RFCA) for persistent atrial fibrillation (AF) is associated with suboptimal long-term outcomes. Although increasing evidence supports substrate-based ablation strategies targeting extra-PV sources, reliable endpoints during CA beyond pulmonary vein (PV) isolation are not well established.
40 Journal of Cardiovascular Electrophysiology
APRIL 2, 2025
The Kaplan-Meier curve of all-atrial arrhythmia-free survival for (A) all persistent patients and (B) patients who underwent PSM conducted to the higher recurrence rate in PVI + group. Methods Data from early commercial use across seven European centers were collected in a registry. Procedural and follow-up data were collected.
Circulation: Arrhythmia and Electrophysiology
DECEMBER 19, 2024
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulmonary vein isolation (PVI) alone is less effective in patients with persistent atrial fibrillation (AF) compared with those with paroxysmal AF. to 3.4%]; hazard ratio, 0.66 [95% CI, 0.460.94]).
Circulation: Arrhythmia and Electrophysiology
JANUARY 29, 2024
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:High-power short-duration ablation has shown impressive efficacy and safety for pulmonary vein isolation (PVI); however, initial efficacy results with very high power short-duration ablation were discouraging. ie, noninferiority is met).
DAIC
DECEMBER 22, 2023
The first procedures were performed by Dr. David Newton , Clinical Cardiac Electrophysiologist at Memorial Health University Physicians Heart Care and Dr. Andrea Natale , Executive Medical Director at T exas Cardiac Arrhythmia Institute, St. David’s Medical Center.
Journal of Cardiovascular Electrophysiology
NOVEMBER 11, 2024
This study of 16 patients with persistent left superior vena cava (PLSVC) undergoing atrial fibrillation ablation shows a 66.7% Abstract Objectives To investigate tailored approaches, techniques, and outcomes of catheter ablation in patients with persistent left superior vena cava (PLSVC) undergoing atrial fibrillation (AF) ablation.
HeartRhythm
MARCH 31, 2025
Pulsed field ablation (PFA) has emerged as a new ablation method for treating atrial fibrillation (AF) through pulmonary vein isolation (PVI).
40 
HeartRhythm
APRIL 16, 2025
Catheter ablation for atrial fibrillation (AF) aims to achieve durable pulmonary vein isolation (PVI) by creating transmural lesions that disrupt arrhythmogenic pathways. However, consistent and lasting success remains challenging due to variability in lesion formation and durability, contributing to arrhythmia recurrence.
40 
Frontiers in Cardiovascular Medicine
JULY 16, 2024
BackgroundAmiodarone is a class III antiarrhythmic drug that is commonly used in the clinic to treat ventricular arrhythmias and atrial fibrillation.
52 
HeartRhythm
MARCH 31, 2025
Large footprint pulse field ablation (PFA) catheters have been widely adopted for pulmonary vein isolation (PVI) and posterior wall isolation (PWI) for atrial fibrillation. The role of large footprint PFA catheters for linear ablation in the treatment of organized atrial arrhythmias has not been well described.
40 
Journal of Cardiovascular Electrophysiology
DECEMBER 7, 2023
Abstract Introduction Earlier studies have shown a clear association between severity of human immunodeficiency virus (HIV) infection and incident atrial fibrillation (AF). During first procedure, all received isolation of pulmonary vein (PV) + posterior wall and superior vena cava. vs. 87.1%, p = .753]
Circulation: Arrhythmia and Electrophysiology
MARCH 21, 2025
Circulation: Arrhythmia and Electrophysiology, Ahead of Print.
HeartRhythm
NOVEMBER 21, 2024
2 BB area pacing defined using P-wave criteria has been associated with decreased atrial arrhythmia burden, recurrence, and de novo incidence compared with right atrial septal pacing and right atrial appendage pacing.3
40 
Journal of Cardiovascular Electrophysiology
OCTOBER 19, 2023
Although the QDOT MICRO™ Catheter was mainly designed for pulmonary vein isolation (PVI) its versatility to treat atrial fibrillation (AF) and other types of arrhythmias was recently evaluated by the FAST and FURIOUS study series and other studies and will be presented in this article.
40 HeartRhythm
FEBRUARY 15, 2024
Pulmonary vein isolation (PVI) has been established as a cornerstone therapy for atrial fibrillation (AF). Despite its effectiveness, over 20% of patients still experience recurrences of AF and atrial tachyarrhythmias (ATs) after PVI.1
40 HeartRhythm
JANUARY 29, 2024
The role of the right atrium (RA) in atrial fibrillation (AF) has long been overlooked. Multiple studies have examined clinical conditions associated with AF, such as atrial enlargement, fibrosis extent, electrical remodeling, and wall thickening, but have been mainly concentrated on the left atrium (LA).
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content